Fresenius Medical Care AG/€FME
1D1W1MYTD1Y5YMAX
Capital at risk
About Fresenius Medical Care AG
Fresenius Medical Care, listed under the ticker FME, is a global provider of dialysis services and products for individuals diagnosed with chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in the healthcare sector. Beyond dialysis, Fresenius Medical Care offers a range of other services, including hospital management and related healthcare services, advancing its position as a comprehensive healthcare provider internationally.
- Ticker
- €FME
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 107,226
- Headquarters
- Bad Homburg, Germany
- Website
- www.freseniusmedicalcare.com
FME Metrics
BasicAdvanced
€10B
11.56
€3.35
0.83
€1.49
3.85%
Price and volume
Market cap
€10B
Beta
0.83
52-week high
€47.84
52-week low
€34.58
Average daily volume
790K
Dividend rate
€1.49
Financial strength
Current ratio
1.071
Quick ratio
0.631
Long term debt to equity
0.638
Total debt to equity
0.811
Dividend payout ratio (TTM)
42.67%
Interest coverage (TTM)
5.20%
Profitability
EBITDA (TTM)
2,721.597
Gross margin (TTM)
26.36%
Net profit margin (TTM)
4.83%
Operating margin (TTM)
10.26%
Effective tax rate (TTM)
20.99%
Revenue per employee (TTM)
€180,000
Management effectiveness
Return on assets (TTM)
3.98%
Return on equity (TTM)
8.52%
Valuation
Price to earnings (TTM)
11.561
Price to revenue (TTM)
0.558
Price to book
0.82
Price to tangible book (TTM)
-3.83
Price to free cash flow (TTM)
6.094
Free cash flow yield (TTM)
16.41%
Free cash flow per share (TTM)
6.348
Dividend yield (TTM)
3.85%
Forward dividend yield
3.85%
Growth
Revenue change (TTM)
-0.46%
Earnings per share change (TTM)
50.07%
3-year revenue growth (CAGR)
-0.33%
10-year revenue growth (CAGR)
2.06%
3-year earnings per share growth (CAGR)
18.11%
10-year earnings per share growth (CAGR)
0.23%
3-year dividend per share growth (CAGR)
9.98%
10-year dividend per share growth (CAGR)
6.65%
What the Analysts think about FME
Analyst ratings (Buy, Hold, Sell) for Fresenius Medical Care AG stock.
Analyst projections of the future price of Fresenius Medical Care AG stock.
Bulls say / Bears say
Second-quarter operating income was well ahead of market expectations and basic EPS of €0.81 beat the €0.68 consensus, underlining effective execution of its cost-cutting programme and disciplined expense management. (Reuters)
Revenue in Q2 2026 rose to €4.86 billion, surpassing the €4.79 billion consensus estimate and demonstrating resilient demand for dialysis products and services despite macroeconomic headwinds. (Reuters)
Favourable U.S. reimbursement rates, including Transitional Drug Add-on Payment Adjustment boosts, helped offset a deepening decline in patient treatment volumes and supported improved profitability in Q2. (Reuters)
U.S. same-market treatment volumes declined by 0.4% in Q1 2026, marking the second consecutive quarter of contraction and highlighting persistent volume pressures in its core U.S. dialysis market. (Reuters)
Fresenius Medical Care faces a potential €1.05 million penalty over alleged corruption in West Africa, as Frankfurt prosecutors seek payment following long-running investigations. (Bloomberg)
Rival DaVita raised its 2026 adjusted profit forecast after beating Q1 earnings estimates, signaling intensifying competition in the global dialysis services market. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
FME Financial Performance
Revenues and expenses
FME Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing FME
AllEURGBPUSD
Fund name | Fund size | €FME weighting |
|---|---|---|
iShares EURO STOXX Mid€DJMC | €572M | 0.93% |
iShares EURO STOXX Mid Cap£DJMC | £491M | 0.93% |
iShares Dax ESG€EXIA | €127M | 0.59% |
iShares Edge MSCI Europe Value Factor€CEMS | €2.6B | 0.51% |
iShares Edge MSCI Europe Value Factor£IEFV | £2.2B | 0.51% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.